News

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...
Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker.